Research Insights on CJC-1295 DAC vs No DAC

If you’ve been looking into peptide therapy for anti-aging, athletic performance, or overall wellness, chances are you’ve come across CJC-1295. The peptide is well-liked for its natural growth hormone-enhancing properties, which support fat loss, faster recovery, and even improved skin health-with no synthetic HGH.

What most people don’t know, however, is that you can administer CJC-1295 in two ways: one “with DAC” (Drug Affinity Complex) and one “without DAC.” So, what’s the real difference, and how do you know which is best for your needs? Here, we’ll break down the basics of CJC-1295, compare DAC and no-DAC, and give you a clear picture of how each can be used for performance, recovery, or anti-aging.

Understanding CJC-12965 and Its Role in Growth Hormone Release

CJC-1295 is a lab-created peptide that’s intended to mimic Growth Hormone-Releasing Hormone (GHRH), the natural signal that tells the pituitary gland to secrete Growth Hormone (GH). In simple terms, it assists the body in making more of its own GH instead of using injections of external hormone.

This increase in GH subsequently raises Insulin-Like Growth Factor 1 (IGF-1) as well, the important hormone that’s ultimately responsible for many of the desired effects of GH, including assisting in lean muscle gain, fat loss, and helping in tissue repair. Unlike the direct intake of synthetic GH, administration of GHRG analog such as CJC-1295 works in harmony with the body’s feedback system, so the process is more balanced and physiologically friendly. In fact, scientists have even said that GHRH-based peptides “stimulate endogenous GH secretion and may provide a safer, more physiologic alternative to direct GH administration.” Why is that significant?

Look at, for instance, adults with GH deficiency: they have greater fat mass and have less muscle mass, yet when levels are sufficiently restored, their body composition and quality of life dramatically improve. Interestingly, GHRH itself also has implications for the brain-studies indicate that it can improve deeper slow-wave sleep, reasons why many who utilize GH peptides report improved rest and quicker recovery alongside physical transformation.

In a nutshell, CJC-1295 basically works as a „signal booster“ for growth hormone. By imitating the body’s own GHRH, it stimulates the pituitary to secrete GH in healthful, thythmic pulses instead of drenching the system. That makes it an attraactive alternative in contemporary peptide therapy regimens, with advantages that include fat reduction and enhanced muscle ton to enhanced repair and even anti-aging effects-without the disadvantages or increased risks of synthetic HGH injections.

CJC-1295 With DAC vs. CJC-1295 No DAC: What Is the Difference?

When researching CJC-1295, you’ll soon discover that it exists in two forms: with DAC (Drug Affinity Complex) and without DAC. At their core, they are the same altered 29-amino acid chain that acts to mimic the function of GHRH. The difference is the “DAC” attachment, a chemical characteristic that prolongs how long the peptide is active in the body. This superficially minor adjustment has a significant effect on how the peptide functions, how frequently it must be administered, and the nature of the growth hormone release created.

Half-Life and Dosing Frequency

The most significant distinction between the two preparations is their duration and how long they are active within the body: CJC-1295 with DAC has a half-life of approximately 6-8 days. Due to the Drug Affinity Complex, the peptide is bound to albumin (a prevalent protein in the blood), which protects it from fast breakdown. As a result, with one injection, GH release can be increased for approximately a week. Indeed, studies have revealed a single dose can maintain GH levels for as much as six days and IGF-1 for 9-11 days.

This longer action makes one or two weekly injections usually sufficient, so it’s an excellent option for those who prefer fewer injections. CJC-1295 with no DAC- “modified GRF 1-29” as it’s often referred to-is much shorter-acting. Without the DAC attachment, the peptide is removed from the body relatively quickly, with a half-life of somewhere between 30 minutes to 2 hours.

In order to deliver continued benefits, it’s generally injected once or twice daily, often in the morning and again before bedtime. The advantage is that each injection delivers a sharp, natural-like spike of GH release, which then returns to baseline, closely mimicking how the body naturally functions. The disadvantage is the commitment to frequent injections.

In brief, the DAC takes longer with less frequent shots, but the no-DAC needs to be administered every day despite being more physiological, pulsatile patterned. Neither one is “better” per se-the ideal varies according to what you’re trying to accomplish, your lifestyle, and your preference for how growth hormone is released in your body.

Growth Hormone Release Pattern: Pulsatile vs. Continuous

The second main difference between the two forms of CJC-1295 is the way they affect the body’s secretion of growth hormones.

CJC-1295 with DAC causes a steady sustained increase in both growth hormones and IGF-1. Because the peptide is active for several days, the pituitary gland is under constant stimulation. The result is a more constant anabolic environment-somewhat similar to low-dose daily HGH therapy-rather than spiky peaks. This release pattern can be ideal for around-the-clock tissue repair, muscle growth, and recovery. The drawback, however, is that body isn’t used to round-the-clock GH exposure.

Normally, GH is received in pulses, mostly during the night, so researchers have expressed some concern that constant stimulation may ultimately reduce receptor sensitivity. Curiously, research shows that even during the long-duration action of CJC-1295 with DAC, the pituitary gland still produces a measure of natural pulsatility, but overall GH and IGF-1 levels are above normal around the clock.

CJC-1295 without DAC does the opposite: it generates a steep spike of GH soon after injection, then levels return to baseline. This “pulsatile” pattern more closely resembles how the body naturally processes GH, with multiple bursts over a 24-hour period, most during deep sleep.

Since the short-acting version clears quickly, the endocrine system gets breaks between doses, allowing normal feedback mechanisms and receptor sensitivity to be preserved. Many clinicians believe this prevents overexposure and allows the pituitary to remain responsive. For this reason, no-DAC is sometimes paired with other secretagogues such as Ipamorelin, which amplifies each pulse.

This pairing can generate a dramatic GH spike, much like that which follows intense exercise or restful sleep. So which release pattern is “better”? It depends on personal goals. Those who desire maximum convenience and a continuous anabolic effect may prefer the DAC version, since it provides high IGF-1 levels with few injections.

But those who desire more of a natural rhythm-or who anticipate long-term peptide use-may choose the no-DAC version in order to minimize potential desensitization. Some even report that short-acting GHRH analogs are safer for long-term administration since the body is allowed to cycle back to baseline between doses. In the end, the choice is between continuous elevation (DAC) or physiological pulses (no DAC)-a difference which can affect both short-term and long-term therapy outcome.

Research

CJC-1295 Peptide and Mechanistic Insights

It was in the year 2006 that two significant clinical trials were carried out to evaluate the effects of CJC-1295 with DAC. Single doses of the peptide at four ascending concentrations were tested in the first trial, while repeated administration at a single concentration was tested in the second. In both trials, there was a clear rise in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) following the administration of CJC-1295 DAC.

The theorized mechanism for the above observations is that CJC-1295 DAC elevates GH secretion, and the latter stimulates the liver to synthesize more IGF-1. GH, by binding with receptors on liver cells, triggers intracellular signaling cascades-most prominently the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. The cascade enables transcription of the IGF-1 gene, the end result of which is the secretion of more IGF-1. Into circulation, IGF-1 can diffuse into various tissues of the body, where it stimulates cell growth, tissue repair, and anabolic activity.

CJC-1295 Peptide and Animal Research

Follow-up studies using animal models have also provided additional data on how CJC-1295 with DAC can influence body composition and growth. In a mouse study, for instance, daily administration of the peptide appeared to restore growth to near normal, whereas every-other day or every-two-to-three-days administration had less pronounced effects. This suggests that frequency of dosing is an important consideration of the action of the peptide.

The study also indicated possible alteration of body composition. Mice administered CJC-1295 DAC exhibited indications of greater muscle hypertrophy in addition to decreased fat tissue when compared to untreated models. When administered to GHRH-knockout mice, treatment with the peptide sustained lean mass and conserved subcutaneous fat to levels comparable to those of healthy controls. By comparison, untreated models had the propensity to deposit greater levels of fat.

At a cellular level, immunohistochemistry analysis revealed CJC-1295 DAC increased total pituitary RNA and GH mRNA. The researchers concluded this was an indication of somatotroph cell proliferation-cells within the pituitary responsible for growth hormone production-a possible mechanism underlying the observed anabolic and metabolic effects.

CJC-1295 Peptide and Infertility

Research from the early 1990s indicates that CJC-1295 and other growth hormone-releasing factor (GRF) analogs can stimulate ovulation in interfile female organisms, as these models were said to exhibit a significant increase of both follicular fluid IGF-1 levels (compared to the previous cycle) and plasma GH levels immediately.

Ovulation is said to be reliant on insulin-like growth factor-1 (IGF-1) and potentially influenced by growth hormone (GH) release and cycling. Research in animal models of superovulation has shown that both GH and IGF-1 levels can rise drastically around the time of ovulation. These results suggest that the exogenous exposure of GH secretagogues, such as CJC-1295, could stimulate proper ovulation.

CJC-1295 (No DAC) Peptide and the Pituitary Gland

CJC-1295 without DAC appears to directly act on GHRH receptors located on the cells of the pituitary gland. By binding to them, the peptide can change their shape in a way that activates an intracellular cascade of signals. Activation of the receptor is thought to activate G-proteins located on the inner face of the cell membrane, initiating a cascade of secondary messengers such as cAMP and IP3. These messengers are amplifiers and carry the signal deeper into the cell.

One of them, notably, is significant, cAMP, which activates protein kinases-enzymes that phosphorylate target proteins. This step of phosphorylation controls a multitude of cellular processes, including the activity of transcription factors. This transcription factor once activated migrate into the cell nucleus, where they affect the expression of genes involved in the synthesis and secretion of growth hormone.

The end result of this signaling cascade is the merging of GH-containing secretory vesicles with the pituitary cell membrane. By this action, growth hormone is secreted into the circulation, where it is free to act on bodily tissues. So, in this way, CJC-1295 without DAC functions as an initiator, provoking the pituitary gland’s own growth hormone secretion ability in response to physiological stimuli.

CJC-1295 (No DAC) Peptide and Intestinal Studies

Studies have investigated the potential for GHRH analogs such as CJC-1295 (No DAC) to act at receptors beyond pituitary. One such receptor of interest has been the VPAC(1)-R receptor on smooth muscle cells of the gastrointestinal tract. Studies suggest that activity at this receptor location could promote bowel motility, altering intestinal movement and digestion. However, the exact nature of the relationship between certain GHRH analog peptides and bowel function remains under investigation, and the correlation is the subject of ongoing research.

CJC-1295 (No DAC) Peptide and Heart Rate

Preclinical studies in murine models have also pointed to possible cardiovascular effects of Modified GRF 1-29 (CJC-1295 without DAC) and other GHRH analogs. Preliminary results suggest that these peptides may be therapeutic for the support of cardiac function, particularly after myocardial injury. In animal studies, treatment with GHRH agonist peptides appeared to enhance cardiac tissue repair, restore normal heart rate, and, in some cases, increase ejection fraction-the amount of blood the heart pumps out with each contraction. These preliminary results indicate the possibility that GHRH analogs may find application in future treatments for cardiac recuperation, but a great deal more research must be conducted before clinical impressions can be determined.

Exploring GLP-1 options for weight management? See where liraglutide fits in the broader picture in our guide: How Liraglutide Fits in the GLP-1 Therapy Landscape.

References:

1. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006.
2. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.
3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
4. Newton, A. C., Bootman, M. D., & Scott, J. D. (2016). Second Messengers. Cold Spring Harbor perspectives in biology, 8(8), a005926. https://doi.org/10.1101/cshperspect.a005926
5. ClinicalTrials.gov, A service of the US National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/NCT00267527 (27 June 2010).
6. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
7. Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943